Old and new markers for breast cancer prognosis: The need for integrated research on quantitative issues

European Journal of Cancer

Volumn 40, Issue 12, 2004, Pages 1803-1806

  Biganzoli, Elia ^a   Boracchi, Patrizia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER GRADING; DNA MICROARRAY; GENE EXPRESSION PROFILING; HEALTH CARE ORGANIZATION; HORMONAL THERAPY; HUMAN; MEDICAL RESEARCH; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SHORT SURVEY; WORLD HEALTH ORGANIZATION;

EID: 3843114803     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.04.026     Document Type: Editorial

References (16)

1. Boracchi P., Biganzoli E. Markers of prognosis and response to treatment: ready for clinical use in oncology? A biostatistician's viewpoint. Int. J. Biol. Markers. 18:2003;65-69
2. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21:2003;3357-3365
3. Eifel P., Axelson J.A., Costa J., Crowley J., Curran W.J. Jr., Deshler A., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. 93:2001;979-989
4. Edén P, Ritz C, Rose C, Fernö M, Peterson C. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004, this issue (doi:10.1016/j.ejca.2004.02.025)
5. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
6. Biganzoli E., Boracchi P., Coradini D., Grazia Daidone M., Marubini E. Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. Ann. Oncol. 14:2003;1484-1493
7. Simon R., Radmacher M.D., Dobbin K., McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl. Cancer. Inst. 95:2003;14-18
8. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl. J. Med. 347:2002;1999-2009
9. Sargent D., Allegra C. Issues in clinical trial design for tumor marker studies. Semin. Oncol. 29:2002;222-230
10. Cardoso F. Microarray technology and its effect on breast cancer (re)classification and prediction of outcome. Breast Cancer Res. 5:2003;303-304
11. Huang E., Cheng S.H., Dressman H., Pittman J., Tsou M.H., Horng C.F., et al. Gene expression predictors of breast cancer outcomes. Lancet. 361:2003;1590-1596
12. Colomer R., Vinas G., Beltran M., Izquierdo A., Lluch A., Llombart-Cussac A., et al. Spanish Breast Cancer Research Group. Validation of the 2001 St. Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). J. Clin. Oncol. 22:2004;961-962
13. Keyomarsi K., Tucker S.L., Buchholz T.A., Callister M., Ding Y., Hortobagyi G.N., et al. Cyclin E and survival in patients with breast cancer. New Engl. J. Med. 347:2002;1566-1575. Erratum in: New Engl J Med 2003, 348, 186
14. Borg A., Ferno M., Peterson C. Predicting the future of breast cancer. Nat. Med. 9:2003;16-18
15. Helmbold P., Haerting J., Kolbl H. Gene-expression signatures in breast cancer. New Engl. J. Med. 348:2003;1715-1717. author reply 1715-7
16. Caldas C., Aparicio S.A. The molecular outlook. Nature. 415:2002;484-485